United States Autoimmune Disorders Diagnostics Market Opportunities, 2020
Autoimmune disorders occur when a person’s immune system attacks his/her own body; and for detecting these disorders and prescribing required treatments, various laboratory tests are performed. Increasing healthcare expenditure, rapidly rising demand for autoimmune disease diagnostics and various ongoing technological advancements leading to the advent of innovative diagnostic procedures are some of the major factors anticipated to drive the United States autoimmune disorders diagnostics market over the next five years. Furthermore, growing disease burden of various autoimmune disorders, especially Rheumatoid Arthritis, Type 1 Diabetes, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), Inflammatory Bowel Disease (IBD), Psoriasis and Autoimmune Thyroiditis, is expected to boost the US autoimmune disorders diagnostics market through 2020.
According to Pharmaion report, “United States Autoimmune Disorders Diagnostics Market Opportunities, 2020”, the autoimmune disorders diagnostics market in the United States is anticipated to cross US$ 6 billion by 2020. On the basis of target disease, the market is broadly segmented into two categories, namely, systemic autoimmune disorders diagnostics and localized autoimmune disorders diagnostics. Among these two categories, systemic autoimmune disorders diagnostics segment dominated the United States autoimmune disorders diagnostics market in 2014. The segment is anticipated to continue its dominance through 2020 on account of increasing ongoing research activities that are focussed on developing tests and technologies that would precisely detect the abnormalities in the organ functioning and thus deliver faster diagnosis. The largest market share in the United States autoimmune disorders diagnostics market was captured by the South-East region, followed by the Midwest, North-East, West and South-West regions. Some of the major players operating in United States autoimmune disorders diagnostics market include Bio-Rad Laboratories, Inc., Roche Diagnostics Corporation, Abbott Laboratories, Danaher Corporation and Siemens Healthcare Diagnostics, Inc., among others. “United States Autoimmune Disorders Diagnostics Market Opportunities, 2020” discusses the following aspects related to United States autoimmune disorders diagnostics market:
The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with diagnostics device manufacturers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.
According to Pharmaion report, “United States Autoimmune Disorders Diagnostics Market Opportunities, 2020”, the autoimmune disorders diagnostics market in the United States is anticipated to cross US$ 6 billion by 2020. On the basis of target disease, the market is broadly segmented into two categories, namely, systemic autoimmune disorders diagnostics and localized autoimmune disorders diagnostics. Among these two categories, systemic autoimmune disorders diagnostics segment dominated the United States autoimmune disorders diagnostics market in 2014. The segment is anticipated to continue its dominance through 2020 on account of increasing ongoing research activities that are focussed on developing tests and technologies that would precisely detect the abnormalities in the organ functioning and thus deliver faster diagnosis. The largest market share in the United States autoimmune disorders diagnostics market was captured by the South-East region, followed by the Midwest, North-East, West and South-West regions. Some of the major players operating in United States autoimmune disorders diagnostics market include Bio-Rad Laboratories, Inc., Roche Diagnostics Corporation, Abbott Laboratories, Danaher Corporation and Siemens Healthcare Diagnostics, Inc., among others. “United States Autoimmune Disorders Diagnostics Market Opportunities, 2020” discusses the following aspects related to United States autoimmune disorders diagnostics market:
- United States Autoimmune Disorders Diagnostics Market Size, Share & Forecast
- Segmental Analysis – By Target Disease, By Test, By Technology & By Region
- Policy & Regulatory Landscape
- Changing Market Trends & Emerging Opportunities
- Competitive Landscape & Strategic Recommendations
- To identify the on-going trends and anticipated growth in the next five years
- To gain competitive knowledge of leading market players
- To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer’s specific needs
The information contained in this report is based upon both primary and secondary sources. Primary research included interviews with diagnostics device manufacturers and industry experts. Secondary research included an exhaustive search of relevant publications like company annual reports, financial reports and other proprietary databases.
1. AUTOIMMUNE DISORDERS DIAGNOSTICS OVERVIEW
2. ANALYST VIEW
3. RESEARCH METHODOLOGY
4. DISEASE EPIDEMIOLOGY
5. GLOBAL AUTOIMMUNE DISORDERS DIAGNOSTICS MARKET OVERVIEW
6. UNITED STATES AUTOIMMUNE DISORDERS DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Target Disease (Systemic Autoimmune Disorders Diagnostics & Localized Autoimmune Disorders Diagnostics)
6.2.2. By Test (Urinalysis, Comprehensive Metabolic Panel, C-reactive Protein, Erythrocyte Sedimentation Rate, Complete Blood Count, Anti-Nuclear Antibody Test & Others)
6.2.3. By Technology (Enzyme Immunoassay, Multiplexed Immunoassays, Immunofluorescence & Others)
6.2.4. By Region (South-West, West, North-East, Midwest, South-East)
7. UNITED STATES ANTI-NUCLEAR ANTIBODY TEST MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type {Others (Anti-centromere Antibodies, Histone Antibody & Nucleolar Antibody), Anti-dsDNA Test & Extractable Nuclear Antigen (ENA) Panel}
8. MARKET DYNAMICS
8.1. Drivers
8.2. Challenges
9. MARKET TRENDS & DEVELOPMENTS
9.1. Increasing Use of Biomarkers
9.2. Lab automation
9.3. Lab-on-Chip Devices
9.4. Portable Diagnostics Equipment
9.5. Partnership with Physician and Diagnostics Laboratories
10. POLICY & REGULATORY LANDSCAPE
11. UNITED STATES ECONOMIC PROFILE
12. COMPETITIVE LANDSCAPE
12.1. Competition Benchmarking (Market Attractiveness)
12.2. Company Profiles
12.2.1. Bio-Rad Laboratories, Inc.
12.2.2. Roche Diagnostics Corporation
12.2.3. Abbott Laboratories
12.2.4. Danaher Corporation
12.2.5. Siemens Healthcare Diagnostics, Inc.
12.2.6. Biomeriux Clinical Diagnostics
12.2.7. Immco Diagnostics
12.2.8. Beckton Dickson
12.2.9. Alere Inc.
12.2.10. Inova Diagnostics, Inc.
13. STRATEGIC RECOMMENDATIONS
2. ANALYST VIEW
3. RESEARCH METHODOLOGY
4. DISEASE EPIDEMIOLOGY
5. GLOBAL AUTOIMMUNE DISORDERS DIAGNOSTICS MARKET OVERVIEW
6. UNITED STATES AUTOIMMUNE DISORDERS DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Target Disease (Systemic Autoimmune Disorders Diagnostics & Localized Autoimmune Disorders Diagnostics)
6.2.2. By Test (Urinalysis, Comprehensive Metabolic Panel, C-reactive Protein, Erythrocyte Sedimentation Rate, Complete Blood Count, Anti-Nuclear Antibody Test & Others)
6.2.3. By Technology (Enzyme Immunoassay, Multiplexed Immunoassays, Immunofluorescence & Others)
6.2.4. By Region (South-West, West, North-East, Midwest, South-East)
7. UNITED STATES ANTI-NUCLEAR ANTIBODY TEST MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type {Others (Anti-centromere Antibodies, Histone Antibody & Nucleolar Antibody), Anti-dsDNA Test & Extractable Nuclear Antigen (ENA) Panel}
8. MARKET DYNAMICS
8.1. Drivers
8.2. Challenges
9. MARKET TRENDS & DEVELOPMENTS
9.1. Increasing Use of Biomarkers
9.2. Lab automation
9.3. Lab-on-Chip Devices
9.4. Portable Diagnostics Equipment
9.5. Partnership with Physician and Diagnostics Laboratories
10. POLICY & REGULATORY LANDSCAPE
11. UNITED STATES ECONOMIC PROFILE
12. COMPETITIVE LANDSCAPE
12.1. Competition Benchmarking (Market Attractiveness)
12.2. Company Profiles
12.2.1. Bio-Rad Laboratories, Inc.
12.2.2. Roche Diagnostics Corporation
12.2.3. Abbott Laboratories
12.2.4. Danaher Corporation
12.2.5. Siemens Healthcare Diagnostics, Inc.
12.2.6. Biomeriux Clinical Diagnostics
12.2.7. Immco Diagnostics
12.2.8. Beckton Dickson
12.2.9. Alere Inc.
12.2.10. Inova Diagnostics, Inc.
13. STRATEGIC RECOMMENDATIONS
LIST OF TABLES
Table 1: United States Average Annual Cost of Diagnosis and Treatment of Autoimmune Disorders, 2014
Table 2: United States Occurrence of Autoimmune Disorders in Males and Females
Table 3: Partial List of Autoimmune Diseases
Table 4: Conditions Associated with Positive Antinuclear Antibody (ANA) Test
Table 5: United States Research Funding for Autoimmune Disorder, By Year, (USD Million)
Table 6: List of Partners of Accelerating Medicine Partnership
Table 1: United States Average Annual Cost of Diagnosis and Treatment of Autoimmune Disorders, 2014
Table 2: United States Occurrence of Autoimmune Disorders in Males and Females
Table 3: Partial List of Autoimmune Diseases
Table 4: Conditions Associated with Positive Antinuclear Antibody (ANA) Test
Table 5: United States Research Funding for Autoimmune Disorder, By Year, (USD Million)
Table 6: List of Partners of Accelerating Medicine Partnership
LIST OF FIGURES
Figure 1: United States Autoimmune Disorders Prevalence per 100,000 Population, 2013
Figure 2: United States Autoimmune Disorders Diagnostics Market Size, By Value, 2010-2020F (USD Billion)
Figure 3: United States Autoimmune Disorders Diagnostics Market Share, By Target Disorder, By Value, 2010-2020F
Figure 4: United States Autoimmune Disorders Diagnostics Market, By Test, By Value, 2010-2020F
Figure 5: United States Autoimmune Disorders Diagnostics Market Share, By Technology, By Value, 2010-2020F
Figure 6: United States Autoimmune Disorders Diagnostics Market Share, By Region, By Value, 2014 & 2020F
Figure 7: United States Autoimmune Disorders Diagnostics Market Share, By Region, By Value, 2010-2020F
Figure 8: United States Anti-Nuclear Antibody Test Market Size, By Value, 2010-2020F (USD Billion)
Figure 9: United States Anti-Nuclear Antibody Test Market Share, By Type, By Value, 2010-2020F
Figure 10: United States Autoimmune Disease Prevalence, 2013 (Million)
COMPANIES MENTIONED
1. Bio-Rad Laboratories, Inc.
2. Roche Diagnostics Corporation
3. Abbott Laboratories
4. Danaher Corporation
5. Siemens Healthcare Diagnostics, Inc.
6. Biomeriux Clinical Diagnostics
7. Immco Diagnostics
8. Beckton Dickson
9. Alere Inc.
10. Inova Diagnostics, Inc.
Figure 1: United States Autoimmune Disorders Prevalence per 100,000 Population, 2013
Figure 2: United States Autoimmune Disorders Diagnostics Market Size, By Value, 2010-2020F (USD Billion)
Figure 3: United States Autoimmune Disorders Diagnostics Market Share, By Target Disorder, By Value, 2010-2020F
Figure 4: United States Autoimmune Disorders Diagnostics Market, By Test, By Value, 2010-2020F
Figure 5: United States Autoimmune Disorders Diagnostics Market Share, By Technology, By Value, 2010-2020F
Figure 6: United States Autoimmune Disorders Diagnostics Market Share, By Region, By Value, 2014 & 2020F
Figure 7: United States Autoimmune Disorders Diagnostics Market Share, By Region, By Value, 2010-2020F
Figure 8: United States Anti-Nuclear Antibody Test Market Size, By Value, 2010-2020F (USD Billion)
Figure 9: United States Anti-Nuclear Antibody Test Market Share, By Type, By Value, 2010-2020F
Figure 10: United States Autoimmune Disease Prevalence, 2013 (Million)
COMPANIES MENTIONED
1. Bio-Rad Laboratories, Inc.
2. Roche Diagnostics Corporation
3. Abbott Laboratories
4. Danaher Corporation
5. Siemens Healthcare Diagnostics, Inc.
6. Biomeriux Clinical Diagnostics
7. Immco Diagnostics
8. Beckton Dickson
9. Alere Inc.
10. Inova Diagnostics, Inc.
